Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App





Testing Saliva as Reliable as Nasal Swab and Detects 93% of COVID-19 Infections, Finds Study

By LabMedica International staff writers
Posted on 23 Aug 2021
A real-world trial has demonstrated that COVID-19 tests of self-collected saliva provided comparable results to tests performed by trained healthcare professionals using Nasopharyngeal (NP) swabs.

Based on their analysis, the researchers from Beth Israel Deaconess Medical Center (Boston, MA, USA) concluded that saliva tests detect 93% of COVID-19 infections in an outpatient setting. The findings could help alleviate the testing bottlenecks that have constrained COVID-19 testing since early in the pandemic.

As the highly transmissible Delta variant of the virus that causes COVID-19 surges in the US and around the world, rapid and accessible COVID-19 testing and increased vaccination are key to managing the virus’ spread. NP swabs - long, medical-grade probes used to collect samples from deep in patients’ noses and throats - are the gold standard for COVID-19 diagnostic testing. However, memory of shortages of both the specialized NP swabs during the early days of the pandemic as well as pressure on the trained medical personnel needed to perform the tests point to the need for simpler COVID-19 testing.

For their study, the researchers obtained two samples – one via NP swab, the other saliva – from 385 patients presenting for COVID-19 testing. Patients waiting in line for NP testing were given a sterile sample collection cup and asked to provide a three milliliter saliva sample. Saliva samples were processed either untreated or treated with a preservative, and all samples were tested across two different COVID-19 testing platforms. After finding that virus particles remained stable in both treated and untreated saliva samples for at least 24 hours, the researchers demonstrated high concordance, or agreement, between saliva testing and NP testing. That is, results came back the same in 93% of cases.

Among the 385 samples taken, just nine had mismatched results between the NP and saliva test results. Most of the mismatches were at very low viral loads, making them clinically less worrisome, and saliva detected as many infections that NP missed, as vice versa. The researchers reported that the sensitivity of NP testing was still slightly higher that of saliva testing, with NP testing able to detect viral particles at lower concentrations. However, the researchers found that saliva testing is still likely to detect 90% of COVID-19 infections, and concluded that the minor loss in sensitivity is outweighed by the ease and safety of self-collection.

“Saliva self-collection is simply easier and more comfortable than the alternative of NP swabs, which in addition to the discomfort also require a trained medical professional,” said Ramy Arnaout, MD, DPhil, associate director of the Clinical Microbiology Laboratories at BIDMC. “In addition to it being a more convenient method, our findings show saliva collection can also be just as effective - even in a real-world scenario in which there are no eating or drinking restrictions before the saliva is collected.”

“We have demonstrated that for practical purposes, saliva is comparable to NP swabs for COVID-19 testing in outpatient settings,” added Arnaout, who is also associate professor of pathology at Harvard Medical School.

Related Links:
Beth Israel Deaconess Medical Center


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.